Skip to main content

Cancer Death Comes Early in India

March 28, 2012 — An estimated 71% of all cancer deaths in India occur in people 30 to 69 years of age, according to a study published online March 28 in the Lancet.
This is a "landmark study" because it is a "nationally representative sample," according to an accompanying comment.
The study provides adequate coverage of often neglected rural areas where three quarters of Indians live, write Rengaswamy Sankaranarayanan, MD, from the International Agency for Research on Cancer in Lyon, France, and Rajaraman Swaminathan, PhD, from the Cancer Institute in Chennai, India, in their comment.
It "represents notable progress in obtaining direct estimates of the cancer burden, particularly in regions that are not covered by cancer registration," they write.
"Verbal autopsy" — and not systematic medical certification — was used to determine the cause of death in the study. Such autopsies, which rely on relatives' accounts of illness, are used in an Indian data-collection system that covers 1.5 million households. The data collection is contributing to a larger ongoing general mortality study, known as the Million Death Study. The study enables a population projection of mortality from the autopsy data.
The fact that so many cancer deaths occur in India before old age is an opportunity, Drs. Sankaranarayanan and Swaminathan suggest. There are "substantial social and economic gains that would be associated with a successful cancer prevention program," they write.
Among men 30 to 69 years of age, about half of all of cancer deaths were from oral and pharyngeal (23%), stomach (13%), and lung (11%) cancers. Among women in the same age group, about half of all cancer deaths were from cervix (17%), stomach (14%), breast (10%), and oral and pharyngeal (10%) cancers.
However, Drs. Sankaranarayanan and Swaminathan cast a somewhat critical eye on the specifics of the cancer mortalities. "For cancer deaths, assigning causes of death to internal cancers such as stomach, liver, bowel, and kidney can be more challenging than for sites such as head and neck, breast, and cervix," they point out.
Nevertheless, the study is a "valuable exercise in improving cancer mortality data in India," they write.
Interventions such as tobacco control, vaccination against human papillomavirus and hepatitis B, cervical cancer screening and early detection, and treatment of oral and breast cancers would have a "substantial effect" on cancer death prevention, they add.
Overall, cancer mortality rates in India are about 40% lower in men and 30% lower in women than in the United States or United Kingdom, they write. However, this will change because cancer death rates are expected to rise, "particularly with increases in age-specific exposure to tobacco smoking," they note.
Data Include Religion, State, and Education
There have been previous mortality estimates for specific cancers in India, but they have heavily relied on data from urban population-based cancer registries, according to the study authors, led by Prabhat Jha, MD, DPhil, from the University of Toronto in Ontario, Canada, who collaborated with colleagues from India and elsewhere.
The Million Death Study is one of the few large nationally representative studies of the causes of death in any low- or middle-income country, say the study authors. The study allows for a better estimation of the causes of death, including cancer, because it is not limited by locale or education level, Drs. Sankaranarayanan and Swaminathan note.
The authors found that 7137 of the 122,429 study deaths were due to cancer, which corresponds to a projected estimate of 556,400 cancer deaths across the whole of India for 2010. About 71% (395,000) of these deaths occurred in people 30 to 69 years of age (200,100 men and 195,300 women), the authors report. Cancer deaths accounted for 6% of deaths across all ages.
Surprisingly, age-standardized cancer mortality rates per 100,000 were similar for men in rural (95.6; 99% confidence interval [CI], 89.6 to 101·7) and urban (102.4; 99% CI, 92.7 to 112.1) areas, and for women in rural (96.6; 99% CI, 90.7 to 102.6) and urban (91.2; 99% CI, 81.9 to 100.5) areas. However, these rates varied greatly between Indian states, with higher rates in poor states.
Level of education influenced mortality, the authors found. The cancer death rates were 2 times higher in the least educated (illiterate) men (106.6; 99% CI, 97.4 to 115.7) than in the most educated men (45.7; 99% CI, 37.8 to 53.6), and in the least educated (illiterate) women (106.7; 99% CI, 99.9 to 113.6) than in themost educated women (43.4; 99% CI, 30.7–56.1).
Cervical cancer was far less common in Muslim women (24 deaths; age-standardized mortality ratio, 0.68; 99% CI, 0.64 to 0.71) than in Hindu women (340 deaths; 1.06 ; 99% CI, 1.05 to 1.08). Circumcision among Muslim men is a "likely explanation," the authors write, saying that it reduces the sexual transmission of human papillomavirus.
The study was funded by the Bill & Melinda Gates Foundation and the US National Institutes of Health.
Lancet. Published online March 28, 2012. Abstract, Comment

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...